80_FR_14197 80 FR 14145 - Notice of Hearing: Reconsideration of Disapproval Louisiana Medicaid State Plan Amendment (SPA) 12-66-B

80 FR 14145 - Notice of Hearing: Reconsideration of Disapproval Louisiana Medicaid State Plan Amendment (SPA) 12-66-B

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services

Federal Register Volume 80, Issue 52 (March 18, 2015)

Page Range14145-14146
FR Document2015-06226

This notice announces an administrative hearing to be held on April 30, 2015, at the Department of Health and Human Services, Centers for Medicare and Medicaid Services, Division of Medicaid & Children's Health, Dallas Regional Office, 1301 Young Street, Room 730, Dallas, TX 75202, to reconsider CMS' decision to disapprove Louisiana's Medicaid SPA 12-66-B. Closing Date: Requests to participate in the hearing as a party must be received by the presiding officer by April 2, 2015.

Federal Register, Volume 80 Issue 52 (Wednesday, March 18, 2015)
[Federal Register Volume 80, Number 52 (Wednesday, March 18, 2015)]
[Notices]
[Pages 14145-14146]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-06226]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services


Notice of Hearing: Reconsideration of Disapproval Louisiana 
Medicaid State Plan Amendment (SPA) 12-66-B

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Notice of hearing: Reconsideration of disapproval.

-----------------------------------------------------------------------

SUMMARY: This notice announces an administrative hearing to be held on 
April 30, 2015, at the Department of Health and Human Services, Centers 
for Medicare and Medicaid Services, Division of Medicaid & Children's 
Health, Dallas Regional Office, 1301 Young Street, Room 730, Dallas, TX 
75202, to reconsider CMS' decision to disapprove Louisiana's Medicaid 
SPA 12-66-B.
    Closing Date: Requests to participate in the hearing as a party 
must be received by the presiding officer by April 2, 2015.

FOR FURTHER INFORMATION CONTACT: Benjamin R. Cohen, Presiding Officer, 
CMS, 2520 Lord Baltimore Drive, Suite L, Baltimore, Maryland 21244, 
Telephone: (410) 786-3169.

SUPPLEMENTARY INFORMATION: This notice announces an administrative 
hearing to reconsider CMS' decision to disapprove Louisiana's Medicaid 
SPA 12-66B which was submitted to the Centers for Medicare and Medicaid 
Services (CMS) on December 20, 2012 and disapproved on December 11, 
2014. In part, this SPA requested CMS approval to revise the current 
pharmacy reimbursement methodology for estimated acquisition cost (EAC) 
which is currently calculated as average acquisition cost (AAC) of the 
drug dispensed to a new calculation of AAC adjusted by a multiplier of 
1.1 for multiple source drugs and 1.01 for single source drugs. In 
addition, propose a reimbursement methodology of wholesale acquisition 
cost (WAC) adjusted by a multiplier of 1.05 for state-defined specialty 
therapeutic classes of drugs.
    The issues to be considered at the hearing are:
     Whether the state's proposed increased payment methodology 
under Louisiana Medicaid SPA 12-66-B complies with the requirements of 
section 1902(a)(30)(A) of the Act which requires, in part, that states 
have methods and procedures to assure that payment rates are consistent 
with efficiency, economy, and quality of care.
     Whether the state demonstrated that the proposed payment 
increases are consistent with the aggregate upper payment limits set in 
implementing regulations at 42 CFR 447.512 which provide that payments 
for drugs are to be based on the lower of: (1) The ingredient EAC of 
the drug and a reasonable dispensing fee; or (2) the provider's usual 
and customary charges to the general public.
     Whether the proposed calculation of EAC used in 
calculating upper payment limits (based on a multiple of the AAC) is 
consistent with the definition of EAC in 42 CFR 447.502, which defines 
EAC as ``the agency's best estimate of the price generally and 
currently paid by providers for a drug marketed or sold by a particular 
manufacturer or labeler in the package size of drug most frequently 
purchased by providers.''
    Section 1116 of the Act and federal regulations at 42 CFR part 430, 
establish Department procedures that provide an administrative hearing 
for reconsideration of a disapproval of a state plan or plan amendment. 
CMS is required to publish a copy of the notice to a state Medicaid 
agency that informs the agency of the time and place of the hearing, 
and the issues to be considered. If we subsequently notify the agency 
of additional issues that will be considered at the hearing, we will 
also publish that notice.
    Any individual or group that wants to participate in the hearing as 
a party must petition the presiding officer within 15 days after 
publication of this notice, in accordance with the requirements 
contained at 42 CFR 430.76(b)(2). Any interested person or organization 
that wants to participate as amicus curiae must petition the presiding 
officer before the hearing begins in accordance with the requirements 
contained at 42 CFR 430.76(c). If the hearing is later rescheduled, the 
presiding officer will notify all participants.
    The notice to Louisiana announcing an administrative hearing to 
reconsider the disapproval of its SPA reads as follows:

J. Ruth Kennedy
State Medicaid Director
Louisiana Department of Health and Hospitals
628 N. 4th Street
P.O. Box 91030
Baton Rouge, LA 70821

Dear Ms. Kennedy:

    I am responding to your request for reconsideration of the 
decision to disapprove Louisiana's Medicaid state plan amendment 
(SPA) 12-66B, which was submitted to the Centers for Medicare and 
Medicaid Services (CMS) on December 20, 2012, and disapproved on 
December 11, 2014. I am scheduling a hearing on your request for 
reconsideration to be held on April 30, 2015, at the Department of 
Health and Human Services, Centers for Medicare and Medicaid 
Services, Division of Medicaid & Children's Health, Dallas Regional 
Office, 1301 Young Street, Room 730, Dallas, TX 75202.
    I am designating Mr. Benjamin R. Cohen as the presiding officer. 
If these arrangements present any problems, please contact Mr. Cohen 
at (410) 786-3169. In order to facilitate any communication that may 
be necessary between the parties prior to the hearing, please notify 
the presiding officer to indicate acceptability of the hearing date 
that has been scheduled and provide names of the individuals who 
will represent the state at the hearing. If the hearing date is not 
acceptable, Mr. Cohen can set another date mutually agreeable to the 
parties. The hearing will be governed by the procedures prescribed 
by federal regulations at 42 CFR part 430.
    In part, this SPA would revise the current pharmacy 
reimbursement methodology for estimated acquisition cost (EAC) which 
is currently calculated as average acquisition cost (AAC) of the 
drug dispensed to a new

[[Page 14146]]

calculation of AAC adjusted by a multiplier of 1.1 for multiple 
source drugs and 1.01 for single source drugs. In addition, this SPA 
would apply a reimbursement methodology of wholesale acquisition 
cost (WAC) adjusted by a multiplier of 1.05 for state-defined 
specialty therapeutic classes of drugs.

The issues to be considered at the hearing are:
     Whether the state's proposed increased payment 
methodology under Louisiana Medicaid SPA 12-66-B complies with the 
requirements of section 1902(a)(30)(A) of the Act which requires, in 
part, that states have methods and procedures to assure that payment 
rates are consistent with efficiency, economy, and quality of care.
     Whether the state demonstrated that the proposed 
payment increases are consistent with the aggregate upper payment 
limits set in implementing regulations at 42 CFR 447.512 which 
provide that payments for drugs are to be based on the lower of: 1) 
the ingredient EAC of the drug and a reasonable dispensing fee; or 
2) the provider's usual and customary charges to the general public.
     Whether the proposed calculation of EAC used in 
calculating upper payment limits (based on a multiple of the AAC) is 
consistent with the definition of EAC in 42 CFR 447.502, which 
defines EAC as ``the agency's best estimate of the price generally 
and currently paid by providers for a drug marketed or sold by a 
particular manufacturer or labeler in the package size of drug most 
frequently purchased by providers.''
    In the event that CMS and the state come to agreement on 
resolution of the issues which formed the basis for disapproval, 
this SPA may be moved to approval prior to the scheduled hearing.

Sincerely,

Andrew M. Slavitt

Section 1116 of the Social Security Act (42 U.S.C. 1316; 42 CFR 
430.18) (Catalog of Federal Domestic Assistance program No. 13.714. 
Medicaid Assistance Program.)

    Dated: March 13, 2015.
Andrew M. Slavitt,
Acting Administrator, Centers for Medicare & Medicaid Services.
[FR Doc. 2015-06226 Filed 3-17-15; 8:45 am]
BILLING CODE 4120-01-P



                                                                                      Federal Register / Vol. 80, No. 52 / Wednesday, March 18, 2015 / Notices                                                                         14145

                                                                                                            ESTIMATED ANNUALIZED BURDEN HOURS—Continued
                                                                                                                                                                                                                                     Average
                                                                                                                                                                                                                    Number of
                                                                                                                                                                                                 Number of                         burden per
                                                                    Type of respondent                                                           Form name                                                        responses per
                                                                                                                                                                                                respondents                         response
                                                                                                                                                                                                                    respondent      (in hours)

                                                  Pathologist ......................................................   Pathology Report—No standard form ............                                         5               1            5/60
                                                  Next-of-kin for deceased miner ......................                2.6 ..................................................................                 5               1           15/60



                                                  Leroy A. Richardson,                                                  dispensed to a new calculation of AAC                                      Any individual or group that wants to
                                                  Chief, Information Collection Review Office,                          adjusted by a multiplier of 1.1 for                                      participate in the hearing as a party
                                                  Office of Scientific Integrity, Office of the                         multiple source drugs and 1.01 for                                       must petition the presiding officer
                                                  Associate Director for Science, Office of the                         single source drugs. In addition,                                        within 15 days after publication of this
                                                  Director, Centers for Disease Control and                             propose a reimbursement methodology                                      notice, in accordance with the
                                                  Prevention.                                                           of wholesale acquisition cost (WAC)                                      requirements contained at 42 CFR
                                                  [FR Doc. 2015–06160 Filed 3–17–15; 8:45 am]                           adjusted by a multiplier of 1.05 for state-                              430.76(b)(2). Any interested person or
                                                  BILLING CODE 4163–18–P                                                defined specialty therapeutic classes of                                 organization that wants to participate as
                                                                                                                        drugs.                                                                   amicus curiae must petition the
                                                                                                                           The issues to be considered at the                                    presiding officer before the hearing
                                                  DEPARTMENT OF HEALTH AND                                                                                                                       begins in accordance with the
                                                                                                                        hearing are:
                                                  HUMAN SERVICES                                                                                                                                 requirements contained at 42 CFR
                                                                                                                           • Whether the state’s proposed
                                                  Centers for Medicare & Medicaid                                       increased payment methodology under                                      430.76(c). If the hearing is later
                                                  Services                                                              Louisiana Medicaid SPA 12–66–B                                           rescheduled, the presiding officer will
                                                                                                                        complies with the requirements of                                        notify all participants.
                                                  Notice of Hearing: Reconsideration of                                 section 1902(a)(30)(A) of the Act which                                    The notice to Louisiana announcing
                                                  Disapproval Louisiana Medicaid State                                  requires, in part, that states have                                      an administrative hearing to reconsider
                                                  Plan Amendment (SPA) 12–66–B                                          methods and procedures to assure that                                    the disapproval of its SPA reads as
                                                                                                                        payment rates are consistent with                                        follows:
                                                  AGENCY: Centers for Medicare &                                                                                                                 J. Ruth Kennedy
                                                  Medicaid Services (CMS), HHS.                                         efficiency, economy, and quality of care.
                                                                                                                                                                                                 State Medicaid Director
                                                  ACTION: Notice of hearing:
                                                                                                                           • Whether the state demonstrated that                                 Louisiana Department of Health and
                                                  Reconsideration of disapproval.                                       the proposed payment increases are                                          Hospitals
                                                                                                                        consistent with the aggregate upper                                      628 N. 4th Street
                                                  SUMMARY:    This notice announces an                                  payment limits set in implementing                                       P.O. Box 91030
                                                  administrative hearing to be held on                                  regulations at 42 CFR 447.512 which                                      Baton Rouge, LA 70821
                                                  April 30, 2015, at the Department of                                  provide that payments for drugs are to                                   Dear Ms. Kennedy:
                                                  Health and Human Services, Centers for                                be based on the lower of: (1) The                                           I am responding to your request for
                                                  Medicare and Medicaid Services,                                       ingredient EAC of the drug and a                                         reconsideration of the decision to disapprove
                                                  Division of Medicaid & Children’s                                     reasonable dispensing fee; or (2) the                                    Louisiana’s Medicaid state plan amendment
                                                  Health, Dallas Regional Office, 1301                                  provider’s usual and customary charges                                   (SPA) 12–66B, which was submitted to the
                                                                                                                        to the general public.                                                   Centers for Medicare and Medicaid Services
                                                  Young Street, Room 730, Dallas, TX
                                                                                                                                                                                                 (CMS) on December 20, 2012, and
                                                  75202, to reconsider CMS’ decision to                                    • Whether the proposed calculation                                    disapproved on December 11, 2014. I am
                                                  disapprove Louisiana’s Medicaid SPA                                   of EAC used in calculating upper                                         scheduling a hearing on your request for
                                                  12–66–B.                                                              payment limits (based on a multiple of                                   reconsideration to be held on April 30, 2015,
                                                     Closing Date: Requests to participate                              the AAC) is consistent with the                                          at the Department of Health and Human
                                                  in the hearing as a party must be                                     definition of EAC in 42 CFR 447.502,                                     Services, Centers for Medicare and Medicaid
                                                  received by the presiding officer by                                  which defines EAC as ‘‘the agency’s best                                 Services, Division of Medicaid & Children’s
                                                  April 2, 2015.                                                                                                                                 Health, Dallas Regional Office, 1301 Young
                                                                                                                        estimate of the price generally and
                                                                                                                                                                                                 Street, Room 730, Dallas, TX 75202.
                                                  FOR FURTHER INFORMATION CONTACT:                                      currently paid by providers for a drug                                      I am designating Mr. Benjamin R. Cohen as
                                                  Benjamin R. Cohen, Presiding Officer,                                 marketed or sold by a particular                                         the presiding officer. If these arrangements
                                                  CMS, 2520 Lord Baltimore Drive, Suite                                 manufacturer or labeler in the package                                   present any problems, please contact Mr.
                                                  L, Baltimore, Maryland 21244,                                         size of drug most frequently purchased                                   Cohen at (410) 786–3169. In order to
                                                  Telephone: (410) 786–3169.                                            by providers.’’                                                          facilitate any communication that may be
                                                  SUPPLEMENTARY INFORMATION: This                                          Section 1116 of the Act and federal                                   necessary between the parties prior to the
                                                                                                                                                                                                 hearing, please notify the presiding officer to
                                                  notice announces an administrative                                    regulations at 42 CFR part 430, establish                                indicate acceptability of the hearing date that
                                                  hearing to reconsider CMS’ decision to                                Department procedures that provide an                                    has been scheduled and provide names of the
                                                  disapprove Louisiana’s Medicaid SPA                                   administrative hearing for                                               individuals who will represent the state at
                                                  12–66B which was submitted to the                                     reconsideration of a disapproval of a                                    the hearing. If the hearing date is not
                                                  Centers for Medicare and Medicaid                                     state plan or plan amendment. CMS is                                     acceptable, Mr. Cohen can set another date
                                                                                                                                                                                                 mutually agreeable to the parties. The
mstockstill on DSK4VPTVN1PROD with NOTICES




                                                  Services (CMS) on December 20, 2012                                   required to publish a copy of the notice
                                                  and disapproved on December 11, 2014.                                 to a state Medicaid agency that informs                                  hearing will be governed by the procedures
                                                  In part, this SPA requested CMS                                       the agency of the time and place of the                                  prescribed by federal regulations at 42 CFR
                                                                                                                                                                                                 part 430.
                                                  approval to revise the current pharmacy                               hearing, and the issues to be considered.                                   In part, this SPA would revise the current
                                                  reimbursement methodology for                                         If we subsequently notify the agency of                                  pharmacy reimbursement methodology for
                                                  estimated acquisition cost (EAC) which                                additional issues that will be considered                                estimated acquisition cost (EAC) which is
                                                  is currently calculated as average                                    at the hearing, we will also publish that                                currently calculated as average acquisition
                                                  acquisition cost (AAC) of the drug                                    notice.                                                                  cost (AAC) of the drug dispensed to a new



                                             VerDate Sep<11>2014        20:26 Mar 17, 2015       Jkt 235001      PO 00000      Frm 00076        Fmt 4703       Sfmt 4703       E:\FR\FM\18MRN1.SGM      18MRN1


                                                  14146                       Federal Register / Vol. 80, No. 52 / Wednesday, March 18, 2015 / Notices

                                                  calculation of AAC adjusted by a multiplier             ACTION: Notification of public meeting;               those products that are non-systemically
                                                  of 1.1 for multiple source drugs and 1.01 for           request for comments.                                 absorbed (locally acting).
                                                  single source drugs. In addition, this SPA                                                                       The assessment of in vivo BE of non-
                                                  would apply a reimbursement methodology                    The Food and Drug Administration                   systemically absorbed drug products has
                                                  of wholesale acquisition cost (WAC) adjusted            (FDA) is announcing a public meeting                  been a longstanding challenge facing
                                                  by a multiplier of 1.05 for state-defined               entitled ‘‘Identification of Alternative In
                                                  specialty therapeutic classes of drugs.
                                                                                                                                                                drug manufacturers and regulators of
                                                                                                          Vitro Bioequivalence Pathways Which                   human and animal health products.
                                                  The issues to be considered at the hearing              Can Reliably Ensure In Vivo
                                                  are:
                                                                                                                                                                Although blood level BE trials remain
                                                                                                          Bioequivalence of Product Performance                 the standard for comparing drug
                                                    • Whether the state’s proposed increased              and Quality of Non-Systemically
                                                  payment methodology under Louisiana                                                                           products that are systemically absorbed
                                                  Medicaid SPA 12–66–B complies with the
                                                                                                          Absorbed Drug Products for Animals’’.                 and that act at a target site reached via
                                                  requirements of section 1902(a)(30)(A) of the           The purpose of the public meeting is to               the blood (systemic circulation), such
                                                  Act which requires, in part, that states have           discuss the use of in vitro methods as                studies cannot confirm product in vivo
                                                  methods and procedures to assure that                   a mechanism for assessing the in vivo                 BE when a drug is either not
                                                  payment rates are consistent with efficiency,           product bioequivalence (BE) of non-                   systemically absorbed or when it is
                                                  economy, and quality of care.                           systemically absorbed drug products                   associated with therapeutic effects
                                                    • Whether the state demonstrated that the             intended for use in veterinary species.               occurring proximal to the site of
                                                  proposed payment increases are consistent               FDA is seeking additional public
                                                  with the aggregate upper payment limits set
                                                                                                                                                                absorption. To date, unless the active
                                                                                                          comment to the docket, and is                         pharmaceutical ingredient met the
                                                  in implementing regulations at 42 CFR
                                                  447.512 which provide that payments for
                                                                                                          requesting that any written comments                  criteria for highly soluble, as defined in
                                                  drugs are to be based on the lower of: 1) the           be submitted by May 18, 2015.                         CVM Guidance #171 entitled ‘‘Waivers
                                                  ingredient EAC of the drug and a reasonable                Date and Time: The public meeting                  of In Vivo Demonstration of
                                                  dispensing fee; or 2) the provider’s usual and          will be held on April 16, 2015, from 9                Bioequivalence of Animal Drugs in
                                                  customary charges to the general public.                a.m. to 4 p.m.                                        Soluble Powder Oral Dosage Form
                                                    • Whether the proposed calculation of                    Location: The public meeting will be               Products and Type A Medicated
                                                  EAC used in calculating upper payment                   held at the Center for Veterinary                     Articles,’’ clinical endpoint BE trials
                                                  limits (based on a multiple of the AAC) is              Medicine (CVM), Food and Drug                         have provided the only option for
                                                  consistent with the definition of EAC in 42             Administration, 7519 Standish Pl., 3rd
                                                  CFR 447.502, which defines EAC as ‘‘the
                                                                                                                                                                generating inter-product comparisons.
                                                                                                          Floor, Conference Room A, Rockville,                  FDA is exploring whether an alternative
                                                  agency’s best estimate of the price generally
                                                                                                          MD 20855. Parking is free.                            in vitro BE approach may be considered
                                                  and currently paid by providers for a drug
                                                  marketed or sold by a particular
                                                                                                             Contact Person: Aleta Sindelar, CVM,               when blood level BE studies are either
                                                  manufacturer or labeler in the package size             Food and Drug Administration, 7519                    not feasible or not appropriate, and
                                                  of drug most frequently purchased by                    Standish Pl., Rm. 144, Rockville, MD                  when products do not meet the criteria
                                                  providers.’’                                            20855, 240–276–9230, FAX: 240–276–                    for applying a Guidance #171-based
                                                    In the event that CMS and the state come              9241, email: BioequivalencePublic                     biowaiver.
                                                  to agreement on resolution of the issues                MeetingRegistration@fda.hhs.gov.                         The assumption underlying the
                                                  which formed the basis for disapproval, this               Registration: Registration is free and             application of the in vitro BE approach
                                                  SPA may be moved to approval prior to the               available on a first-come, first-served               is that equivalence in product
                                                  scheduled hearing.                                      basis. Persons interested in requesting               physicochemical attributes and in vitro
                                                  Sincerely,                                              an opportunity to speak during the open               product performance translates to
                                                  Andrew M. Slavitt                                       public comment period must register by                equivalence in product in vivo behavior.
                                                  Section 1116 of the Social Security Act (42             April 8, 2015, and must include a brief               For sponsors with a right of reference to
                                                  U.S.C. 1316; 42 CFR 430.18) (Catalog of                 summary of comments with their                        underlying safety and effectiveness data,
                                                  Federal Domestic Assistance program No.                 registration. Those individuals will be               the criteria for similarity of
                                                  13.714. Medicaid Assistance Program.)                   contacted prior to the meeting regarding              physicochemical attributes would be
                                                    Dated: March 13, 2015.                                their participation. Persons interested in            defined on the basis of the underlying
                                                  Andrew M. Slavitt,                                      attending this meeting who are not                    dataset to confirm the comparability of
                                                  Acting Administrator, Centers for Medicare
                                                                                                          requesting an opportunity to speak at                 the original formulation and pre- and
                                                  & Medicaid Services.                                    the meeting must register by April 14,                post-approval changes in formulation or
                                                  [FR Doc. 2015–06226 Filed 3–17–15; 8:45 am]
                                                                                                          2015. For general questions about the                 method of product manufacture. In the
                                                                                                          meeting, for assistance registering for               case of generic products, a more rigid
                                                  BILLING CODE 4120–01–P
                                                                                                          the meeting, to request an opportunity                approach to sameness would be used in
                                                                                                          to make an oral presentation, or to                   terms of product composition and
                                                  DEPARTMENT OF HEALTH AND                                request special accommodations due to                 physicochemical characteristics. In both
                                                  HUMAN SERVICES                                          a disability, contact Aleta Sindelar (see             situations, physicochemical
                                                                                                          Contact Person). Please include your                  comparisons would be based upon a
                                                  Food and Drug Administration                            name, organization, and contact                       battery of in vitro test procedures,
                                                                                                          information. Early registration for the               including a comparison of in vitro
                                                  [Docket No. FDA–2015–N–0684]                            meeting is encouraged due to limited                  dissolution behavior under a range of
                                                                                                          time and space.                                       physiologically-relevant conditions.
                                                  Identification of Alternative In Vitro                  SUPPLEMENTARY INFORMATION:                               Examples of the kinds of products
mstockstill on DSK4VPTVN1PROD with NOTICES




                                                  Bioequivalence Pathways Which Can                                                                             where in vitro bioequivalence concepts
                                                                                                          I. Background                                         can potentially be applied include some
                                                  Reliably Ensure In Vivo Bioequivalence
                                                  of Product Performance and Quality of                      Given the imprecision and logistic                 orally administered products (e.g., Type
                                                  Non-Systemically Absorbed Drug                          challenges associated with clinical                   A medicated articles), solutions,
                                                  Products for Animals; Public Meeting                    endpoint BE studies, FDA is exploring                 emulsions, ointments, creams,
                                                                                                          alternative pathways that can be applied              suspensions, transdermal products, and
                                                  AGENCY:    Food and Drug Administration,                to help ensure the equivalence of                     intra-mammary formulations. Due to
                                                  HHS.                                                    product performance and quality for                   unique issues raised by products


                                             VerDate Sep<11>2014   19:00 Mar 17, 2015   Jkt 235001   PO 00000   Frm 00077   Fmt 4703   Sfmt 4703   E:\FR\FM\18MRN1.SGM   18MRN1



Document Created: 2018-02-21 09:39:27
Document Modified: 2018-02-21 09:39:27
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice of hearing: Reconsideration of disapproval.
DatesRequests to participate in the hearing as a party must be received by the presiding officer by April 2, 2015.
ContactBenjamin R. Cohen, Presiding Officer, CMS, 2520 Lord Baltimore Drive, Suite L, Baltimore, Maryland 21244, Telephone: (410) 786-3169.
FR Citation80 FR 14145 

2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR